One concern was that the efficacy of Lp‐PLA2 inhibitors in improving the outcomes in well‐managed statin‐treated patients was limited, as statins could not only inhibit plasma Lp‐PLA2 levels but also could reduce the occurrence of CHD events.158 A different concern was the rationality of the inclusion criteria for the population under study. This evidence concerns the gene PLA2G7 and coronary artery disorder.